ArticleMarine drugs2019
Chlorophyll Derivatives from Marine Cyanobacteria with Lipid-Reducing Activities.
Article in Marine drugs, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 49 citations in OpenAlex.
- UPLC-ESI-TOF-MS Profiling of Metabolome Alterations in Barley (Journal of agricultural and food chemistry · 2025Article
- Unveiling the Biotechnological Potential of Cyanobacteria from the Portuguese LEGE-CC Collection Through Lipidomics and Antioxidant and Lipid-Lowering Properties.Molecules (Basel, Switzerland) · 2025Article
- Chemical diversity of cyanobacterial natural products.Natural product reports · 2025Review
- Actinomycetota From Macroalgae as Rich Source for Natural Products Discovery Revealed Through Culture-Dependent and -Independent Approaches.Microbial biotechnology · 2024Article
- Effect ofInternational journal of molecular sciences · 2024Article
- Green synthesis of chlorella-derived carbon dots and their fluorescence imaging in zebrafish.RSC advances · 2024Article
- Metabolite Profile Characterization of Cyanobacterial Strains with Bioactivity on Lipid Metabolism Using In Vivo and In Vitro Approaches.Marine drugs · 2023Article
- Recent Reports on Bioactive Compounds from Marine Cyanobacteria in Relation to Human Health Applications.Life (Basel, Switzerland) · 2023Review
- Article
- Potential Anti-Obesity, Anti-Steatosis, and Anti-Inflammatory Properties of Extracts from the MicroalgaeMarine drugs · 2021Article
- Uncovering the Bioactive Potential of a Cyanobacterial Natural Products Library Aided by Untargeted Metabolomics.Marine drugs · 2021Article
- Inhibition of Intestinal Lipid Absorption by Cyanobacterial Strains in Zebrafish Larvae.Marine drugs · 2021Article
- Effects of Ethanol Extracts fromMarine drugs · 2021Article
- Natural Compounds for the Prevention and Treatment of Cardiovascular and Neurodegenerative Diseases.Foods (Basel, Switzerland) · 2020Review
- The Marine SeagrassMarine drugs · 2020Article
- Application of Bioactive Thermal Proteome Profiling to Decipher the Mechanism of Action of the Lipid Lowering 13Marine drugs · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 1 institution in 1 country.
Funding
Abstract
Marine organisms, particularly cyanobacteria, are important resources for the production of bioactive secondary metabolites for the treatment of human diseases. In this study, a bioassay-guided approach was used to discover metabolites with lipid-reducing activity. Two chlorophyll derivatives were successfully isolated, the previously described 13
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.